Congenital Myotonic Dystrophy Trial Now Recruiting
The NMD4C is excited to share that an international randomized, multicenter, double-blind, placebo-controlled, phase 2/3 clinical trial testing the safety and efficacy of Tideglusib in Congenital Myotonic Dystrophy (CDM) patients aged 6-16 has begun recruiting. This is the first CDM trial to take place in Canada, even though CDM is one of the more common neuromuscular diseases in Canada, affecting more than one in 50,000 live births. The two Canadian sites are the Children’s Hospital London Health Sciences Centre (LHSC) in London, ON and the Children’s Hospital of Eastern Ontario (CHEO) in Ottawa, ON, with Drs. Craig Campbell and Hanns Lochmüller as Principal Investigators.
Both the London and Ottawa sites are open for recruitment; contact information for both sites is located below. If you would like to learn more about the eligibility criteria and for further information, please visit the ClinicalTrials.gov site to find detailed information!
LHSC site: Rhiannon Hicks, , (519)-685-8441.
CHEO site: Emilie Hill-Smith, , 613-737-7600 ext. 4014.
Read next...
2027 NMD4C–RARE.Qc Basic Science Research Summer School Applications Are Now Open!
Deadline: December 1, 2026
2027 NMD4C–RARE.Qc Basic Science Research Summer School Applications Are Now Open!
The summer school offers neuromuscular and rare disease research trainees the opportunity to participate in an intensive three-day training program focused on cutting-edge experimental and translational research techniques.
